Newsletter Tool

To view this email as a web page, click here

Today's Rundown

Feds call halt to Johnson & Johnson COVID-19 vaccine rollout after 'extremely rare' blood clot cases
CDC study examines racial and ethnic disparities in COVID-19 hospitalizations
Gerngross' Adagio starts testing antibody in COVID-19 patients
Gilead nixes Veklury COVID-19 trial as vaccines roll out, more convenient drugs emerge for outpatients
COVID-19 tracker: EU probes J&J for clarification over vaccine delay; Rigel touts oral drug data in hospitalized patients
UPDATED Coronavirus tracker: White House says J&J vaccine pause won't affect rollout
Resilience keeps expansion spree rolling with buyout of biologics maker Ology

Featured Story

Feds call halt to Johnson & Johnson COVID-19 vaccine rollout after 'extremely rare' blood clot cases

By Eric Sagonowsky

After drug regulators on both sides of the Atlantic revealed safety probes into Johnson & Johnson’s COVID-19 vaccine, U.S. officials have called for an immediate pause to the rollout.

CDC study examines racial and ethnic disparities in COVID-19 hospitalizations

By Robert King

A new CDC study found racial and ethnic minorities had a higher proportion of COVID-19 hospitalizations than whites.

Gerngross' Adagio starts testing antibody in COVID-19 patients

By Nick Paul Taylor

Tillman Gerngross’ Adagio Therapeutics has begun recruitment in a clinical trial of anti-SARS-CoV-2 antibody ADG20. The study is assessing the effect of a single dose of ADG20 on patients with mild to moderate COVID-19 and a high risk of disease progression.

Gilead nixes Veklury COVID-19 trial as vaccines roll out, more convenient drugs emerge for outpatients

By Angus Liu

Gilead Sciences has been exploring its antiviral remdesivir for COVID-19 in the outpatient setting, hoping to replicate the success seen in hospitalized patients. But as new treatments emerge, the company now thinks the drug, in its current form, simply doesn’t have a role to play outside hospitals.

COVID-19 tracker: EU probes J&J for clarification over vaccine delay; Rigel touts oral drug data in hospitalized patients

By Noah Higgins-Dunn,Fraiser Kansteiner,Eric Sagonowsky

The European Commission is asking J&J for clarification surrounding its decision to halt vaccine deliveries to the EU. Several states and retail pharmacy chains are suspending J&J's shot following calls from federal health officials. Rigel finds fostamatinib may help treat hospitalized COVID-19 patients. And more headlines.

UPDATED Coronavirus tracker: White House says J&J vaccine pause won't affect rollout

By Healthcare Staff

Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.

Resilience keeps expansion spree rolling with buyout of biologics maker Ology

By Fraiser Kansteiner

National Resilience is wasting no time building out its biomanufacturing network, which it promised would be the “world’s most advanced" when it launched in November. After buying a pair of commercial facilities last month, Resilience has snapped up biologics drug substance specialist Ology Bioservices.

COVID-19 Tracker